Sana Biotechnology, Inc. $SANA Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC raised its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 26.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,377 shares of the company’s stock after purchasing an additional 8,673 shares during the quarter. Hsbc Holdings PLC’s holdings in Sana Biotechnology were worth $65,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SANA. Millennium Management LLC increased its stake in Sana Biotechnology by 604.8% during the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company’s stock valued at $1,188,000 after purchasing an additional 625,481 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Sana Biotechnology by 44.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock valued at $2,538,000 after purchasing an additional 478,596 shares in the last quarter. Nuveen LLC acquired a new position in Sana Biotechnology during the 1st quarter valued at approximately $589,000. Two Sigma Investments LP increased its stake in Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock valued at $783,000 after purchasing an additional 334,042 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Sana Biotechnology by 87.9% during the 1st quarter. Deutsche Bank AG now owns 666,392 shares of the company’s stock valued at $1,120,000 after purchasing an additional 311,692 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SANA. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Morgan Stanley began coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $8.00.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $2.96 on Monday. The firm has a fifty day moving average price of $3.71 and a 200 day moving average price of $2.70. Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $7.30. The stock has a market cap of $703.92 million, a PE ratio of -2.79 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. As a group, equities analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.